Perrigo Seb Prev label

Perrigo Seb Prev

Perrigo Seb Prev Recall

Get an alert when a recall is issued.

Side Effects & Adverse Reactions

Sulfonamides are known to cause Stevens-Johnson syndrome in hypersensitive individuals. Stevens-Johnson syndrome also has been reported following the use of sulfacetamide sodium topically. Cases of drug-induced systemic lupus erythematosus from topical sulfacetamide also have been reported. In one of these cases, there was a fatal outcome.

FDA Safety Alerts

There are currently no FDA safety alerts available for this drug.

Manufacturer Warnings

There is currently no manufacturer warning information available for this drug.

FDA Labeling Changes

There are currently no FDA labeling changes available for this drug.

Uses

Seb-Prev™ Gel is intended for topical application in the following scaling dermatoses: seborrheic dermatitis and seborrhea sicca (dandruff). It also is indicated for the treatment of secondary bacterial infections of the skin due to organisms susceptible to sulfonamides.

History

There is currently no drug history available for this drug.

Other Information

Each gram of Seb-Prev™ Gel contains 100 mg of Sulfacetamide Sodium USP in a vehicle consisting of edetate disodium, glycerin, methylparaben, propylene glycol, purified water, sodium thiosulfate, and xanthan gum.

Sulfacetamide sodium is C8H9N2NaO3S•H2O with a molecular weight of 254.24. Chemically, it is Acetamide N-[(4-aminophenyl)sulfonyl]-, monosodium salt, monohydrate, with the following structural formula:

structural formula

Sulfacetamide sodium is an odorless, white, crystalline powder with a bitter taste. It is freely soluble in water, sparingly soluble in alcohol, while practically insoluble in benzene, in chloroform, and in ether.

Perrigo Seb Prev Manufacturers

  • Perrigo New York Inc
    Perrigo Seb Prev | Perrigo New York Inc
    No Recall

    Perrigo Seb Prev | Perrigo New York Inc

    Perrigo Seb Prev | Perrigo New York Inc

    Seborrheic dermatitis including seborrhea sicca: Apply to affected areas twice daily (morning and evening), or as directed by your physician. Avoid contact with eyes or mucous membranes. Repeat application as described for eight to ten days.

    As the condition subsides, the interval between applications may be lengthened. Applications once or twice weekly or every other week may prevent recurrence. Should the condition recur after stopping therapy, the application of Seb-Prev™ Gel should be reinitiated as at the beginning of treatment.

    Secondary cutaneous bacterial infections: Apply to affected areas twice daily for eight to ten days.

  • Perrigo New York Inc
    Perrigo Seb Prev | Perrigo New York Inc
    No Recall

    Perrigo Seb Prev | Perrigo New York Inc

    Perrigo Seb Prev | Perrigo New York Inc

    Seborrheic dermatitis including seborrhea sicca: Apply to affected areas twice daily (morning and evening), or as directed by your physician. Avoid contact with eyes or mucous membranes. Repeat application as described for eight to ten days. As the condition subsides, the interval between applications may be lengthened. Applications once or twice weekly or every other week may prevent recurrence. Should the condition recur after stopping therapy, the application of Seb-Prev™ Cream should be reinitiated as at the beginning of treatment.

    Secondary cutaneous bacterial infections: Apply to affected areas twice daily for eight to ten days.